Home › Research › Biomarkers
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Lu M, Kim MJ, Collins EC, Shcherbinin S, Ellinwood AK, Yokoi Y, Brooks DA, Hansson O et al.. JAMA neurology, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Reduction of amyloid via amyloid-targeting therapies may result in clinical benefit. Results Analyses included 1582 participants, including 766 treated with donanemab and 816 with placebo.
What this study adds
Evidence grade: High
This is a trial of 1,582 participants. This secondary analysis of a randomized trial included 1,582 participants, with 766 receiving donanemab and 816 receiving placebo, and noted that reducing amyloid may result in clinical benefit. Reported effect size: 56.9%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lu, M., Kim, M. J., Collins, E. C., Shcherbinin, S., Ellinwood, A. K., Yokoi, Y., et al. (2025). Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA neurology. https://doi.org/10.1001/jamaneurol.2025.3869
Vancouver
Lu M, Kim MJ, Collins EC, Shcherbinin S, Ellinwood AK, Yokoi Y, et al. Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA neurology. 2025. doi:10.1001/jamaneurol.2025.3869. PMID: 41082199.
BibTeX
@article{lu2025-41082199,
author = {Lu, M. and Kim, M. J. and Collins, E. C. and Shcherbinin, S. and Ellinwood, A. K. and Yokoi, Y. and Brooks, D. A. and Hansson, O. and others},
title = {{Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
journal = {JAMA neurology},
year = {2025},
doi = {10.1001/jamaneurol.2025.3869},
pmid = {41082199},
url = {https://doi.org/10.1001/jamaneurol.2025.3869}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Reduction of amyloid via amyloid-targeting therapies may result in clinical benefit.
- Results Analyses included 1582 participants, including 766 treated with donanemab and 816 with placebo.
Why it matters
This secondary analysis of a randomized trial included 1,582 participants, with 766 receiving donanemab and 816 receiving placebo, and noted that reducing amyloid may result in clinical benefit. It reports on posttreatment amyloid levels and clinical outcomes but does not provide a cure or prevention for Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designclinical trial
- Participants1,582
- Effect size56.9%
- Evidence strengthHigh
How this study scored 76/100
Published in a leading specialty journal, and it is a large phase 3 trial.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,582 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 3 / 7 | Cited 32 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 17.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 2 / 4 | Cited 32 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Mark A. Mintun: h-index 131 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Mayo Clinic: institution h-index 1,606 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41082199) |
| Free to read | 2 / 2 | Free to read |
| Total | 76 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2025.3869
- PubMed: 41082199
- Original source →
- Free full text: JAMA Neurology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.